NASDAQ:ALNY

Alnylam Pharmaceuticals Stock News

etoro logo Buy ALNY
*Your capital is at risk
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutic
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recogn
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Bamco Inc. NY bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commissio
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, "Fool me once, shame on you; fool me twice, shame on me." Well, the buy-the-dip crowd
Anchor Investment Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1,024.5% during the third quarter, according to the company in its most recent filing with the Sec

How Alnylam Stock Weathers Market Shocks

11:55am, Wednesday, 11'th Mar 2026
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experience

Alnylam to Webcast TTR Investor Webinar

08:00am, Tuesday, 10'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the In
Fieldview Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the undefined quarter, according to the company in its most recent disclosure with the S
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-eight research firms that are covering the stock, Marketbeat.com report
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY).
Tenaya Therapeutics said on Thursday it has signed a research ​deal with Alnylam Pharmaceuticals worth up ‌to $1.13 billion to develop treatments for heart diseases.
Agreement Combines Tenaya's Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Mill
Elo Mutual Pension Insurance Co lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 26.5% in the third quarter, according to the company in its most recent disclosure with
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE